Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical stage biotechnology company developing immune-modulating therapies centered on the CD40 Ligand (CD40L) pathway. The company’s news flow largely reflects progress with its lead investigational product, tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand that Eledon describes as having broad therapeutic potential.
News updates for ELDN commonly cover clinical trial milestones in kidney allograft transplantation, islet cell transplantation, xenotransplantation and amyotrophic lateral sclerosis (ALS). For example, Eledon has issued press releases on Phase 2 BESTOW trial results in de novo kidney transplant recipients, highlighting kidney function outcomes, safety and tolerability compared with tacrolimus-based regimens. Additional announcements have detailed updated data from a Phase 1b open-label kidney transplant study and long-term extension work.
Another recurring theme in Eledon’s news is the use of tegoprubart in islet transplantation for individuals with type 1 diabetes. The company has reported preliminary results from an investigator-initiated trial at the University of Chicago Medicine’s Transplant Institute, describing insulin independence and improved glycemic control in the first treated subjects. Eledon also issues updates on tegoprubart’s role in xenotransplantation, including its use as a key component of immunosuppression regimens in pig-to-human kidney transplant procedures at Massachusetts General Hospital.
Investors following ELDN news can also expect announcements related to scientific conference presentations, participation in healthcare conferences, financing transactions such as underwritten public offerings of common stock and pre-funded warrants, and selected financial results. This news page aggregates such disclosures so readers can review Eledon’s reported clinical data, corporate developments and regulatory-related communications over time.
Eledon Pharmaceuticals (NASDAQ: ELDN) plans to announce its financial results for Q1 2021 on May 13, 2021, after trading closes. The management will conduct a conference call and webcast at 4:30 PM ET to discuss these results. The company focuses on developing therapies for autoimmune diseases and ALS, with its lead compound AT-1501 targeting the CD40L pathway. This innovative approach aims to improve safety and efficacy in treatments. A recording of the event will be available on Eledon's website for one year.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced a new development strategy for AT-1501 in renal transplantation as requested by the FDA. The agency has asked for specific non-human primate data before starting a Phase 2 trial in the U.S. Consequently, Eledon will conduct evaluations in primate models, expected to be completed by late 2022. Despite this shift, other development programs continue as planned, and no safety concerns regarding AT-1501 have been reported. The CEO emphasized the potential of AT-1501 as a treatment option for renal transplant patients.
Eledon Pharmaceuticals has announced the appointments of David Hovland, Ph.D. as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer. Dr. Hovland brings over 20 years of R&D experience, previously serving at Urovant Sciences and Allergan, while Mr. Smith has a successful track record at Urovant and Allergan. Their expertise is expected to advance the development of AT-1501, a novel antibody targeting the CD40 ligand. The company will issue stock options as inducement grants for their roles.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its fourth quarter and full-year 2020 results, highlighting a net loss of $5.9 million for Q4 and $22.8 million for the year. The company has $114.2 million in cash as of December 31, 2020, allowing it to fund multiple Phase 2 trials of its lead asset, AT-1501. Key milestones include ongoing ALS trials and islet cell transplantation trials expected to start in Q2 2021. The acquisition of Anelixis Therapeutics in September 2020 has reshaped Eledon's focus on autoimmune diseases and transplantation.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its financial results for Q4 and the full year 2020 on March 30, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET. The company, focused on developing treatments for autoimmune diseases and ALS, is advancing its lead compound, AT-1501, a targeted anti-CD40L antibody. Eledon aims to provide enhanced therapeutic solutions in immunology and transplantation.
Eledon Pharmaceuticals has appointed Jeff Bornstein, M.D. as Chief Medical Officer effective April 5, 2021, and Paul Little as Chief Financial Officer immediately. These appointments aim to strengthen the leadership team as Eledon advances its Phase 2 trial of AT-1501 for ALS and plans for additional trials. Dr. Bornstein has extensive experience in biopharmaceuticals, previously working with major companies like Takeda and Biogen, while Mr. Little brings over 30 years of finance and operations expertise from roles in Sientra and Allergan. Both executives will receive inducement grants of stock options.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a clinical stage biopharmaceutical company, announced that CEO David-Alexandre C. Gros, M.D. will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10. The presentation will be available on-demand starting March 9 at 7:00 am EST. Eledon focuses on developing targeted treatments for organ transplantation and immunological diseases, with its lead compound AT-1501, an anti-CD40L antibody aimed at improving immune regulation.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that CEO David-Alexandre C. Gros, M.D. will present at the 10th annual SVB Leerink Global Healthcare Conference on February 24 at 4:20 p.m. EST. The live webcast can be accessed through Eledon's website, and a replay will be available for 90 days. Eledon focuses on developing targeted medicines for organ transplantation and immunological diseases, with its lead compound, AT-1501, targeting the CD40L pathway to potentially enhance treatment efficacy and safety.
Eledon Pharmaceuticals, a clinical-stage biopharmaceutical company focused on treatments for organ transplantation and immunological diseases, announced participation in the Noble Capital Markets' Seventeenth Annual Investor/Equity Conference. CEO David-Alexandre C. Gros will present on January 20 at 9:00 AM ET. The company is developing AT-1501, an anti-CD40L antibody aimed at improving safety and efficacy in treating autoimmune conditions and enhancing transplant success. Interested parties can access a webcast of the presentation on Eledon's website.